CELC — Celcuity Inc.

Is CELC overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Celcuity Inc. (CELC) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $58.01. The rating moved from Oversold to Strong Oversold on November 16, 2026.

See all oversold Healthcare stocks →

AI analysis

Celcuity Inc. (CELC) is a small-cap oncology diagnostics/therapeutics company with proprietary biomarker capabilities that could unlock higher-value partnerships and targeted trial outcomes. Near-term performance will be driven by clinical readouts, partnering progress, and financing clarity; the current market backdrop of consolidation limits momentum for speculative healthcare names. Given limited public financial detail and higher development and liquidity risks, the near-term outlook is balanced between upside from positive newsflow and downside from typical small‑biotech binary events.

Key factors

  • Early-stage, specialized oncology diagnostics/therapeutics focus with potential for high-value companion diagnostic partnerships
  • Proprietary biomarker platforms that can enable targeted patient selection and higher trial success probabilities
  • Visible catalysts in the medium term (clinical readouts, potential licensing or collaboration announcements) that could re-rate the stock
  • Limited public financial disclosures and thin trading liquidity typical of small-cap biotechs, increasing price sensitivity to news flow
  • Current broad market tone is consolidation, which reduces near-term momentum for speculative biotech names
  • Potential for strategic interest from larger diagnostics or pharma players given industry consolidation trends in specialty franchises

Risks

  • Clinical development risk: negative or inconclusive trial/data readouts could materially reduce valuation
  • Financing risk: limited cash runway or need for dilutive capital raises if milestones or partnerships do not materialize
  • Regulatory and reimbursement risk: uncertainty around payer coverage for novel diagnostics or companion assays
  • Competitive risk from larger diagnostics firms or alternative biomarker approaches that could limit market adoption
  • Liquidity and volatility risk: low float can cause large price swings on limited news or trades
  • Limited public financial/reporting data increases uncertainty for fundamental valuation
  • Macro/sector rotation risk: risk-off moves or shifts into defensive large-cap healthcare could depress speculative small-cap biotech performance

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for CELC — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.